Bulk Paclitaxel

Summary

World bulk paclitaxel market stands enthused by the effervescent levels of research and development. With market participants injecting resources into developing unique paclitaxel formulations, emergence of new disease indications is expected to result in expanded market opportunities in the medium to long run. For instance, development of paclitaxel-coated coronary stents will help further improve the use and sales of paclitaxel. With patent expiries leading to the influx of generic forms of paclitaxel, competition is expected to intensify and result in price reductions.

These and other market data and trends are presented in "Bulk Paclitaxel: A Global Update of Market Trends & Opportunities" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Contents

• 1.Methodology
  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Quantitative Techniques & Reporting Level
• 2.Industry Overview
  • Paclitaxel - Leading from The Front
  • US Market - Magnificently Outdistancing Others
  • Cancer Blockbusters - Facing The Brunt
  • A Sunrise Opportunity
  • Bms' Reign Comes to An End
  • Exploring New Avenues
  • Falling Prices - Boon for The Customers, Bane for The Companies
  • All The Strangle for Peanuts?
  • Factors Affecting The Market
  • Paclitaxel Versus Abraxane
• 3.Outlook
  • Competitive Scenario
  • Cancer Generics - A Time for Optimism
  • The US Piazza
• 4.Product Facts
• 5.Research and Development
  • Angiotech Unfurls New Dimensions for Paclitaxel
  • Clinical Research Favors Paclitaxel for Breast Cancer Treatment
  • American Bioscience' Nab Technology Unveils Higher Tissue Penetration Potential
  • Naturol Develops Unique Extraction Technology for Producing Paclitaxel from Canadian Yew
  • Ivax Corp.'s Xorane Revolutionizes The Delivery of Paclitaxel
• 6.Corporate Developments
  • Sonus to Merge with Oncogenex
  • Acusphere Signs Licensing Deal with Cephalon
  • Sonus Terminates Tocosol Paclitaxel Development Program
  • Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel
  • Pliva Lachema Receives Anda for Paclitaxel Injection
  • Cell Therapeutics Receives Emea Acceptance
  • Abraxis Wins Approval for Abraxane in Korea
  • Boston Scientific Obtains Approval for Taxus Liberte from Health Canada
  • Cell Therapeutics Renames Xyotax as Opaxio
  • Dabur Launches Cancer Drug
  • Hospira Takes over Mayne Pharma
  • Protherics to Acquire Macromed
  • Abraxis Acquires Arizona Production Facility
  • Indena Inks Worldwide License Agreement with Spectrum Pharma
  • Bioxel Bags Major Paclitaxel Order
  • Bioxel Enters into Supply Agreement
  • Bioxel Bags Paclitaxel Supply Contract
  • Indena Establishes New Plant to Produce Synthetic Paclitaxel
  • Abraxis Selects Korean Green Cross to Market Abraxane
  • Abraxis Grants License to Biocon for Marketing Abraxane
  • Bioxel Registers Docetaxel with US Fda
  • Bayer Quashes Tocosol Paclitaxel License with Sonus
  • Abraxis' Abraxane Convinces European Chmp
  • Abraxis Receives Approval for Abraxane in Australia
  • Eurocor Receives Ce Mark
  • Supergen Divests Certain Drugs to Intas
  • Abraxis Plans Separation of Oncology Business
  • Dabur Introduces Nanoxel
• 7.Major Players
  • Abraxis Bioscience, Inc. (USA)
  • Bristol-Myers Squibb Co. (USA)
  • Hospira, Inc. (USA)
  • Indena S.P.A. (Italy)
  • Oncogenex Pharmaceuticals, Inc. (USA)
  • Teva Pharmaceuticals USA, Inc. (USA)
• 8.Market Analytics
• 9.The United States
  • Rising Demand for Paclitaxel
  • Alarming Growth of Breast Cancer
  • Clinical Research Favors Paclitaxel for Breast Cancer Treatment
  • Paclitaxel - An Important Element
  • Corporate Talk
  • Drug-Eluting Stents - Marching Ahead
• 10.Rest of World
  • Europe
  • European Market Overview
  • European Market Battling Cost- Containment Woes
  • Efforts to Improve The Scenario and Their Effect on Paclitaxel Market
  • China
  • Chinese Government Strategizing to save Paclitaxel Reserves
• Exhibits
  • Table 1: Global Bulk Paclitaxel Market by Region for The Period 2007-2015 (Sales in Kilograms)
  • Table 2: Percentage Breakdown (Volume Sales) of Global Bulk Paclitaxel Market by Region for The Years 2008 &
  • Table 3: Global Bulk Paclitaxel Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 4: Percentage Breakdown (Dollar Sales) of Global Bulk Paclitaxel Market by Region for The Years 2008 &
  • Table 5: Bulk Paclitaxel Market in The US: 2007-2015 (Sales in Kilograms)
  • Table 6: Bulk Paclitaxel Market in The US: 2007-2015 (Sales in US$ Million)
  • Table 7: Bulk Paclitaxel Market in Rest of World: 2007-2015 (Sales in Kilograms)
  • Table 8: Bulk Paclitaxel Market in Rest of World: 2007-2015 (Sales in US$ Million)Companies Profiled